Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial

详细信息    查看全文

• 作者：Hiroyuki Nishi ; Koichi Toda ; Shigeru Miyagawa ; Yasushi Yoshikawa…
• 关键词：Tolvaptan ; Postoperative care ; Surgery ; Diuretics ; Valvular diseases
• 刊名：Surgery Today
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：45
• 期：12
• 页码：1542-1551
• 全文大小：763 KB
• 参考文献：1.Gandhi A, Husain M, Salhiyyah K, Raja SG. Does perioperative furosemide usage reduce the need for renal replacement therapy in cardiac surgery patients? Interact CardioVasc Thorac Surg. 2012;15:750鈥?.PubMedCentral CrossRef PubMed
  2.Sirivella S, Gielchinsky I, Parsonnet V. Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery. Ann Thorac Surg. 2000;69:501鈥?.CrossRef PubMed
  3.Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol. 2011;58:897鈥?03.CrossRef PubMed
  4.Sica D, Oren RM, Gottwald MD. Mills RM; Scios 351 Investigators. Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction. Clin Cardiol. 2010;33:330鈥?.CrossRef PubMed
  5.Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797鈥?05.PubMedCentral CrossRef PubMed
  6.Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72:1787鈥?3.CrossRef PubMed
  7.Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860鈥?.PubMed
  8.Miyazaki T, Yamamura Y, Onogawa T, Nakamura S, Kinoshita S, Nakayama S, et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology. 2005;146:3037鈥?3.CrossRef PubMed
  9.Gheorghiade M, Gattis WA, O鈥機onnor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963鈥?1.CrossRef PubMed
  10.Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319鈥?1.CrossRef PubMed
  11.Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540鈥?.CrossRef PubMed
  12.Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33鈥?5.CrossRef PubMed
  13.Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013;53:1277鈥?5.PubMedCentral CrossRef PubMed
  14.Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients鈥攁ssociation between non-responders and chronic kidney disease. Circ J. 2013;77:397鈥?04.CrossRef PubMed
  15.Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014;78:844鈥?2.CrossRef PubMed
  16.Hendren WG, Higgins TL. Immediate postoperative care of the cardiac surgical patient. Semin Thorac Cardiovasc Surg. 1991;3:3鈥?2.PubMed
  17.Lim E, Ali ZA, Attaran R, Cooper G. Evaluating routine diuretics after coronary surgery: a prospective randomized controlled trial. Ann Thorac Surg. 2002;73:153鈥?.CrossRef PubMed
  18.Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol. 2000;11:97鈥?04.PubMed
  19.Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med. 1991;114:886鈥?4.CrossRef PubMed
  20.Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17鈥?2.PubMedCentral CrossRef PubMed
  21.Tsukui H. Yamazaki K Contemporary strategy for aortic valve stenosis in octogenarians. Surg Today. 2014;44:992鈥?003.CrossRef PubMed
  22.Abramow M. Cogan E Clinical aspects and pathophysiology of diuretic-induced hyponatremia. Adv Nephrol Necker Hosp. 1984;13:1鈥?8.PubMed
  23.Shirakabe A, Hata N, Yamamoto M, Kobayashi N, Shinada T, Tomita K, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J. 2014;78:911鈥?1.CrossRef PubMed
  24.Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation. 2009;119:2444鈥?3.CrossRef PubMed
  25.Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O鈥機onnor CM, Califf RM, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064鈥?.PubMedCentral CrossRef PubMed
  26.Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S67鈥?6.CrossRef PubMed
  27.Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J. 2014;78:2240鈥?.CrossRef PubMed
  
• 作者单位：Hiroyuki Nishi (1)
  Koichi Toda (1)
  Shigeru Miyagawa (1)
  Yasushi Yoshikawa (1)
  Satsuki Fukushima (1)
  Masashi Kawamura (1)
  Daisuke Yoshioka (1)
  Tetsuya Saito (1)
  Takayoshi Ueno (1)
  Toru Kuratani (1)
  Yoshiki Sawa (1)
  
  1. Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2, Yamada-Oka, Suita, Osaka, 565-0871, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Surgery
  Abdominal Surgery
  Thoracic Surgery
  Vascular Surgery
  Cardiac Surgery
  Surgical Oncology
  
• 出版者：Springer Japan
• ISSN：1436-2813

文摘

Purpose The purpose of this study was to assess the efficacy of tolvaptan, a vasopressin V2 receptor agonist, for the management of postoperative surgical fluid retention after heart valve surgery.